MTMR4 SNVs modulate ion channel degradation and clinical severity in congenital long QT syndrome: insights in the mechanism of action of protective modifier genes.
Cells, Cultured
Genes, Modifier
Genetic Predisposition to Disease
Humans
Induced Pluripotent Stem Cells
/ metabolism
KCNQ1 Potassium Channel
/ genetics
Long QT Syndrome
/ genetics
Mutation
Myocytes, Cardiac
/ metabolism
Nedd4 Ubiquitin Protein Ligases
/ genetics
Phenotype
Polymorphism, Single Nucleotide
Protein Tyrosine Phosphatases, Non-Receptor
/ genetics
Proteolysis
Arrhythmias
Induced pluripotent stem cells
Long QT syndrome
MTMR4
Nedd4L
Variants
Journal
Cardiovascular research
ISSN: 1755-3245
Titre abrégé: Cardiovasc Res
Pays: England
ID NLM: 0077427
Informations de publication
Date de publication:
22 02 2021
22 02 2021
Historique:
received:
04
12
2019
revised:
23
12
2019
accepted:
22
01
2020
pubmed:
17
3
2020
medline:
5
1
2022
entrez:
17
3
2020
Statut:
ppublish
Résumé
In long QT syndrome (LQTS) patients, modifier genes modulate the arrhythmic risk associated with a disease-causing mutation. Their recognition can improve risk stratification and clinical management, but their discovery represents a challenge. We tested whether a cellular-driven approach could help to identify new modifier genes and especially their mechanism of action. We generated human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) from two patients carrying the same KCNQ1-Y111C mutation, but presenting opposite clinical phenotypes. We showed that the phenotype of the iPSC-CMs derived from the symptomatic patient is due to impaired trafficking and increased degradation of the mutant KCNQ1 and wild-type human ether-a-go-go-related gene. In the iPSC-CMs of the asymptomatic (AS) patient, the activity of an E3 ubiquitin-protein ligase (Nedd4L) involved in channel protein degradation was reduced and resulted in a decreased arrhythmogenic substrate. Two single-nucleotide variants (SNVs) on the Myotubularin-related protein 4 (MTMR4) gene, an interactor of Nedd4L, were identified by whole-exome sequencing as potential contributors to decreased Nedd4L activity. Correction of these SNVs by CRISPR/Cas9 unmasked the LQTS phenotype in AS cells. Importantly, the same MTMR4 variants were present in 77% of AS Y111C mutation carriers of a separate cohort. Thus, genetically mediated interference with Nedd4L activation seems associated with protective effects. Our finding represents the first demonstration of the cellular mechanism of action of a protective modifier gene in LQTS. It provides new clues for advanced risk stratification and paves the way for the design of new therapies targeting this specific molecular pathway.
Identifiants
pubmed: 32173736
pii: 5804882
doi: 10.1093/cvr/cvaa019
pmc: PMC7898949
doi:
Substances chimiques
KCNQ1 Potassium Channel
0
KCNQ1 protein, human
0
Nedd4 Ubiquitin Protein Ligases
EC 2.3.2.26
Nedd4L protein, human
EC 2.3.2.26
MTMR4 protein, human
EC 3.1.3.48
Protein Tyrosine Phosphatases, Non-Receptor
EC 3.1.3.48
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
767-779Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Eur Heart J. 2013 Oct;34(40):3109-16
pubmed: 23509228
Int J Cardiol. 2017 Aug 1;240:367-371
pubmed: 28433559
Heart Rhythm. 2011 Apr;8(4):541-7
pubmed: 21129503
Eur Heart J. 2018 Nov 21;39(44):3925-3931
pubmed: 30215713
Hum Mol Genet. 2013 Apr 1;22(7):1395-403
pubmed: 23300193
Cardiovasc Res. 2007 Apr 1;74(1):64-74
pubmed: 17289006
J Am Coll Cardiol. 2013 Jul 16;62(3):169-180
pubmed: 23684683
PLoS One. 2012;7(7):e40288
pubmed: 22815737
Nat Protoc. 2013 Jan;8(1):162-75
pubmed: 23257984
Cell Reprogram. 2010 Dec;12(6):641-53
pubmed: 20858051
Gene. 2015 Feb 25;557(2):113-22
pubmed: 25527121
Trends Biochem Sci. 2018 Aug;43(8):635-647
pubmed: 30056838
Circ Genom Precis Med. 2018 Jan;11(1):e000043
pubmed: 29874173
J Am Coll Cardiol. 2012 Sep 11;60(11):1001-4
pubmed: 22749307
Circ Cardiovasc Genet. 2009 Dec;2(6):558-64
pubmed: 20031635
Cardiovasc Res. 2005 Aug 15;67(3):476-86
pubmed: 15935335
Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R285-92
pubmed: 12925573
Circulation. 2001 Jan 2;103(1):89-95
pubmed: 11136691
J Clin Invest. 2018 Mar 01;128(3):1043-1056
pubmed: 29431731
J Biol Chem. 1998 Mar 20;273(12):6837-43
pubmed: 9506986
J Biol Chem. 2013 Dec 27;288(52):36841-54
pubmed: 24214981
Circulation. 2009 Nov 3;120(18):1761-7
pubmed: 19841298
Int J Cardiol. 2017 Jun 15;237:49-52
pubmed: 28408106
Cardiovasc Res. 2017 Apr 1;113(5):531-541
pubmed: 28158429
Biochem J. 2009 Apr 1;419(1):57-63
pubmed: 19125695
Eur Heart J. 2018 Apr 21;39(16):1446-1455
pubmed: 29020304
Arrhythm Electrophysiol Rev. 2019 Mar;8(2):105-110
pubmed: 31114684
J Physiol. 2000 Feb 15;523 Pt 1:67-81
pubmed: 10675203
Circ Res. 2008 Dec 5;103(12):1451-7
pubmed: 19008479
Channels (Austin). 2011 Jan-Feb;5(1):79-88
pubmed: 21057195
Circ Res. 2006 Nov 10;99(10):1076-83
pubmed: 17053194
Front Physiol. 2015 Feb 03;6:7
pubmed: 25691870
J Mol Cell Cardiol. 2011 Jul;51(1):90-8
pubmed: 21463633
J Biol Chem. 2009 Feb 20;284(8):5250-6
pubmed: 19114714
Circ Res. 2019 Aug 30;125(6):653-658
pubmed: 31465267
Eur Heart J. 2019 Jun 14;40(23):1832-1836
pubmed: 30753398